DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

A Prospective Clinical Study for Laparoscopic D3 Dissection With Preservation of Left Colic Artery in Rectal Cancer

Not Applicable

Conditions: Rectal Neoplasms

Interventions: Procedure: left colic artery
Procedure: High ligation

First Posted Date: 2016-04-27

Last Posted Date: 2016-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT02753465

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Not Applicable

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Other: control
Drug: sorafenib
Drug: aspirin

First Posted Date: 2016-04-22

Last Posted Date: 2019-02-15

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT02748304

Locations: 🇨🇳
Huashan hospital, Shanghai, China

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Phase 2

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: goserelin acetate
Drug: flutamide
Drug: leuprolide acetate
Drug: triptorelin
Procedure: Definitive Treatment

First Posted Date: 2016-04-19

Last Posted Date: 2020-07-07

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT02742675

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Phase 3

Withdrawn

Conditions: Gastric Cancer

Interventions: Drug: S-1 for 6 months
Drug: S-1 for 1 year

First Posted Date: 2016-04-13

Last Posted Date: 2019-05-08

Lead Sponsor: Fudan University

Registration Number: NCT02736552

Locations: 🇨🇳
Anqing Municipal Hospital, Anqing, Anhui, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

and more 7 locations

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Conditions: Prostate Cancer

Interventions: Other: Blood drawing

First Posted Date: 2016-03-30

Last Posted Date: 2016-03-31

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT02723526

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Health Effects of Indoor Air Filtration in Healthy Chinese Adults

Not Applicable

Completed

Conditions: Blood Pressure

Interventions: Behavioral: Air Purifiers
Behavioral: Sham Air Purifiers

First Posted Date: 2016-03-18

Last Posted Date: 2017-10-02

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT02712333

Locations: 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China

Use of Cyclosporin A for the Treatment of Recurrent Miscarriage

Phase 2

Conditions: Miscarriage, Recurrent

Interventions: Drug: Cyclosporin A
Drug: Dydrogesterone

First Posted Date: 2016-03-11

Last Posted Date: 2016-03-15

Lead Sponsor: Fudan University

Target Recruit Count: 384

Registration Number: NCT02706470

Locations: 🇨🇳
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abraxane

First Posted Date: 2016-02-22

Last Posted Date: 2021-03-01

Lead Sponsor: Fudan University

Target Recruit Count: 81

Registration Number: NCT02687490

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Phase 3

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Cisplatin Combined With S-1
Drug: Cisplatin Combined With Paclitaxel

First Posted Date: 2016-02-09

Last Posted Date: 2016-02-09

Lead Sponsor: Fudan University

Target Recruit Count: 268

Registration Number: NCT02677597

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer

Not Applicable

Conditions: Breast Cancer

Interventions: Other: Mutation analysis

First Posted Date: 2016-02-02

Last Posted Date: 2016-02-02

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT02670668

Locations: 🇨🇳
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy